AbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET

Company Participants

Liz Shea - Senior Vice President, Investor Relations
Robert A. Michael - C hief Executive Officer
Jeffrey R. Stewart - Executive Vice President, Chief Commercial Officer
Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer
Scott T. Reents - Executive Vice President, Chief Financial Officer
Carrie Strom - Senior Vice President, AbbVie and President, Global Allergan Aesthetics

Conference Call Participants

Chris Schott - J.P. Morgan
Mohit Bansal - Wells Fargo
Vamil Divan - Guggenheim Securities
Terence Flynn - Morgan Stanley
Chris Shibutani - Goldman Sachs
Trung Huynh - UBS
Geoff Meacham - Citi
James Shin - Deutsche Bank
Carter Gould - Barclays
Steve Scala - Cowen
Luisa Hector - Berenberg

Operator

Good morning, and thank you for standing by. Welcome to the AbbVie Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only until the question-and-answer portion of this call. [Operator Instructions] Today’s call is being recorded.

I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.

Liz Shea

Good morning and thanks for joining us.

Also on the call with me today are Rob Michael, Chief Executive Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer; Scott Reents, Executive Vice President, Chief Financial Officer; and Carrie Strom, Senior Vice President, AbbVie and President, Global Allergan Aesthetics.

Before we get started, I’ll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements, except as required by law.

On today’s conference call, non-GAAP financial measures will be used to help investors understand AbbVie’s business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we’ll take your questions.

So with that, I’ll turn the call over to Rob.

Robert A. Michael

Thank you, Liz. Good morning, everyone, and thank you for joining us.

AbbVie is performing exceptionally well, and I’m extremely pleased with the execution against our strategic priorities, including continued double-digit sales growth from our ex-Humira platform, the closing and integration of Cerevel Therapeutics and the progress we are making to build and advance a compelling pipeline of innovative medicines.